The Impact of CAR T-Cell Therapy on Cancer Care

Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, discusses the emergence of CAR T-cell therapy as a groundbreaking oncology treatment.

At the 2018 National Association of Specialty Pharmacy (NASP) Annual Meeting and Educational Conference,

Cheryl Allen, BSPharm, MBA, Vice President of Industry Relations at Diplomat Pharmacy, discussed novel therapies in cancer care, including the emergence of CAR T-cell therapy as a groundbreaking oncology treatment.

Transcript

You know, when we look at very novel therapies, the CAR T therapy is just fascinating. When we think about the ability to engineer a living cell to combat the patient’s cancer, it’s groundbreaking. What we see now in CAR T, and we’re looking at cancer therapy, we’re going to see that go all throughout different disease states and really begin to drilldown into precision therapy.